Table 7.
Symptom change of the total intention-to-treat-sample and patients with and without migratory background.
| Total sample T0-T1 | Patients without MB T0-T1 | Patients with MB T0-T1 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| T | p | d | T | p | d | T | p | d | |
| PHQ-15 | 5.892 | <0.001 | -0.264 | 5.957 | <0.001 | -0.304 | 1.401 | 0.167 | -0.138 |
| PHQ-15 * | 5.998 | <0.001 | -0.274 | 5.949 | <0.001 | -0.311 | 1.572 | 0.122 | -0.155 |
| PHQ-9 | 12.217 | <0.001 | -0.681 | 11.114 | <0.001 | -0.692 | 5.056 | <0.001 | -0.649 |
| GAD-7 | 9.136 | <0.001 | -0.573 | 8.560 | <0.001 | -0.605 | 3.246 | 0.002 | -0.441 |
| PCL-5 | 3.951 | <0.001 | -0.190 | 3.951 | <0.001 | -0.204 | 1.225 | 0.227 | -0.152 |
MB, migratory background; PHQ-15, Patient Health Questionnaire Somatization Module;* without Menstruation Item; PHQ-9, Patient Health Questionnaire Depression Module; GAD-7, General Anxiety Disorder Short Scale; PCL-5, PTSD-Checklist for DSM-5; varying sample sizes; significant p-values and the corresponding effect sizes are marked in bold.